These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

622 related items for PubMed ID: 9645167

  • 1. Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma.
    Rodriguez M.
    Acta Radiol Suppl; 1998; 417():1-36. PubMed ID: 9645167
    [Abstract] [Full Text] [Related]

  • 2. [18F] FDG PET in gastric non-Hodgkin's lymphoma.
    Rodriguez M, Ahlström H, Sundín A, Rehn S, Sundström C, Hagberg H, Glimelius B.
    Acta Oncol; 1997; 36(6):577-84. PubMed ID: 9408147
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma.
    Ambrosini V, Rubello D, Castellucci P, Nanni C, Farsad M, Zinzani P, Alavi A, Tehranipour N, Al-Nahhas A, Fanti S.
    Nucl Med Rev Cent East Eur; 2006; 9(1):37-40. PubMed ID: 16791802
    [Abstract] [Full Text] [Related]

  • 4. Predicting malignancy grade with PET in non-Hodgkin's lymphoma.
    Rodriguez M, Rehn S, Ahlström H, Sundström C, Glimelius B.
    J Nucl Med; 1995 Oct; 36(10):1790-6. PubMed ID: 7562044
    [Abstract] [Full Text] [Related]

  • 5. 18F-FDG uptake and its clinical relevance in primary gastric lymphoma.
    Yi JH, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS.
    Hematol Oncol; 2010 Jun; 28(2):57-61. PubMed ID: 19593742
    [Abstract] [Full Text] [Related]

  • 6. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G.
    Blood; 1999 Jul 15; 94(2):429-33. PubMed ID: 10397709
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    J Clin Oncol; 2001 Jan 15; 19(2):414-9. PubMed ID: 11208833
    [Abstract] [Full Text] [Related]

  • 8. CT in malignancy grading and prognostic prediction of non-Hodgkin's lymphoma.
    Rodriguez M, Rehn SM, Nyman RS, Sundström JC, Ahlström H, Glimelius BL.
    Acta Radiol; 1999 Mar 15; 40(2):191-7. PubMed ID: 10080733
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
    Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN.
    Leuk Lymphoma; 2000 Nov 15; 39(5-6):543-53. PubMed ID: 11342337
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
    Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau JL, Chatal JF, Couturier O.
    Ann Hematol; 2006 Nov 15; 85(11):759-67. PubMed ID: 16871391
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J, Qiao W, Wang C, Wang T, Xing Y.
    Hematology; 2007 Oct 15; 12(5):423-30. PubMed ID: 17852456
    [Abstract] [Full Text] [Related]

  • 15. Differential Diagnosis of Sinonasal Lymphoma and Squamous Cell Carcinoma on CT, MRI, and PET/CT.
    Kim SH, Mun SJ, Kim HJ, Kim SL, Kim SD, Cho KS.
    Otolaryngol Head Neck Surg; 2018 Sep 15; 159(3):494-500. PubMed ID: 29661053
    [Abstract] [Full Text] [Related]

  • 16. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
    Yang DH, Min JJ, Jeong YY, Ahn JS, Kim YK, Cho SH, Chung IJ, Bom HS, Kim HJ, Lee JJ.
    Ann Hematol; 2009 May 15; 88(5):425-32. PubMed ID: 19002686
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.
    Albano D, Bertoli M, Ferro P, Fallanca F, Gianolli L, Picchio M, Giubbini R, Bertagna F.
    Eur J Nucl Med Mol Imaging; 2017 Apr 15; 44(4):589-597. PubMed ID: 27619357
    [Abstract] [Full Text] [Related]

  • 20. Role of FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour.
    Graziosi L, Bugiantella W, Cavazzoni E, Cantarella F, Porcari M, Baffa N, Donini A.
    Ann Ital Chir; 2011 Apr 15; 82(2):125-9. PubMed ID: 21682102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.